The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity
Open accessAbstract
Accompanied by the growing clinical applications of immunotherapy in the treatment of cancer patients, development of novel therapeutic approaches to reverse the immune‐suppressive environment in cancer patients is eagerly anticipated, because the success of cancer immunotherapy is currently limited by immune‐suppressive effects in tumor‐bearing hosts. Interleukin (IL)‐6, a pleotropic proinflammatory cytokine, participates in tumor cell‐autonomous processes that are required for their survival and growth, and is therefore known as a poor prognostic factor in cancer patients. In addition, an emerging role of IL‐6 in modulating multiple functions of immune cells including T cells, dendritic cells, and macrophages is responsible for the dysfunction of innate and adaptive immunity against tumors. Therefore, the IL‐6‐targeting approach is of value as a promising strategy for desensitization and prevention of immune‐suppressive effects, and should be an effective treatment when combined with current immunotherapies. The aim of the present review is to discuss the immune‐suppressive aspects of IL‐6, notably with modification of T‐cell functions in cancer patients, and their relationship to anti‐tumor immune responses and cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 2×
“In contrast, tumor cells express several molecules that induce T-cell tolerance or exhaustion.(4,9) Treatment with Abs against the immune-checkpoint molecules, most”
BackgroundRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 2×
“In addition to IL-6, elevated levels of sIL-6R have been proposed as a poor prognostic factor in patients with certain types of cancer,(27) because they promote IL-6 stabilization and amplify IL-6 signaling through protecting IL-6 from rapid degradation in vivo.(26) sIL-6R is produced by the shedding of membrane-bound…”
BackgroundSystemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963
Understanding immunosenescence to improve responses to vaccines
Goronzy, J. J., & Weyand, C. M. (2013) · Nature Immunology · doi:10.1038/ni.2588 · Cited by 827 · cited 1×
“de novo supply, and qualitative dysfunction of T cells are responsible for the age-associated decrease in T-cell immunity.(44,45) In addition to T-cell intrinsic dysfunction,(44-46) age-related increases in IL-6 (referred to as inflamm-aging(25,32)) should be taken into consideration in”
BackgroundCarstens, J. L., Correa de Sampaio, P., Yang, D., Barua, S., Wang, H., Rao, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2017) · Nature Communications · doi:10.1038/ncomms15095 · Cited by 633
Senescence-associated inflammatory responses: aging and cancer perspectives
Lasry, A., & Ben-Neriah, Y. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.009 · Cited by 408
Haynes, L., Eaton, S. M., Burns, E. M., Randall, T. D., & Swain, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2433717100 · Cited by 270 · cited 1×
“Furthermore, considering the importance of CD4 T cells in establishment of memory responses in durable anti-tumor immunity,(2) IL-6-mediated defective CD4 T-cell responses may also contribute to the depression of de novo memory response in aged hosts.(46)”
BackgroundKitamura, H., Kamon, H., Sawa, S.-I., Park, S.-J., Katunuma, N., Ishihara, K., Murakami, M., & Hirano, T. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.010 · Cited by 223
Inflammation amplifier, a new paradigm in cancer biology
Atsumi, T., Singh, R., Sabharwal, L., Bando, H., Meng, J., Arima, Y., Yamada, M., Harada, M., Jiang, J.-J., Kamimura, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2322 · Cited by 217
Tsukamoto, H., Clise-Dwyer, K., Huston, G. E., Duso, D. K., Buck, A. L., Johnson, L. L., Haynes, L., & Swain, S. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910139106 · Cited by 166 · cited 1×
“de novo supply, and qualitative dysfunction of T cells are responsible for the age-associated decrease in T-cell immunity.(44,45) In addition to T-cell intrinsic dysfunction,(44-46) age-related increases in IL-6 (referred to as inflamm-aging(25,32)) should be taken into consideration in”
BackgroundSelf-citationTsukamoto, H., Senju, S., Matsumura, K., Swain, S. L., & Nishimura, Y. (2015) · Nature Communications · doi:10.1038/ncomms7702 · Cited by 104
Self-citationTsukamoto, H., Fujieda, K., Hirayama, M., Ikeda, T., Yuno, A., Matsumura, K., Fukuma, D., Araki, K., Mizuta, H., Nakayama, H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2446 · Cited by 53 · cited 8×
“entiation of Th1/Th2 subsets (T-bet, GATA-3), nor the frequencies of Foxp3Treg, RORctTh17, or CXCR5Tfh cells.(17,32) Although the functional requirement of STAT3 for IL-6-mediated Th1 inhibition has been shown,(17) the roles of other components, IL-6-mediated ERK or PI3K activation in modulating Th1 differentiation, r…”
BackgroundResultInfluentialSelf-citation
Cited by
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Senescent cell clearance by the immune system: Emerging therapeutic opportunities
Prata, L. G. P. L., Ovsyannikova, I. G., Tchkonia, T., & Kirkland, J. L. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.003 · Cited by 497
Machine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma
Long, Z., Sun, C., Tang, M., Wang, Y., Ma, J., Yu, J., Wei, J., Ma, J., Wang, B., Xie, Q., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00415-0 · Cited by 109
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31
Metadata
- Authors
- Tsukamoto, H., Fujieda, K., Senju, S., Ikeda, T., Oshiumi, H., & Nishimura, Y.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2017-11-16
- Volume
- 109
- Issue
- 3
- Pages
- 523-530
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2766225245
- Cited by
- 167
- References
- 16
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.